TickerFacts.

Company research / UTHR

United Therapeutics Corp (UTHR)

Build a valuation ↗↓ Download CSV

SEC name UNITED THERAPEUTICS Corp · CIK 0001082554 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, United Therapeutics Corp reported revenue of $3.18B. Revenue grew 10.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.15B.

Key ratios (year ended 2025-12-31)

87.9%
Gross margin (computed)
46.9%
Operating margin
41.9%
Net margin
18.8%
Return on year-end equity
10.6%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-21

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$3.15B$3.18B$2.88B$2.33B$1.94B$1.69B$1.48B$1.45B$1.63B$1.73B$1.60B
Cost of Revenue$437.20M$384.40M$309.70M$257.50M$151.60M$122.50M$108.10M$117.60M$198.70M$105.70M$72.70M
Gross Profit (computed)$2.72B$2.80B$2.57B$2.07B$1.78B$1.56B$1.38B$1.33B$1.43B$1.62Bn/a
R&D Expense$551.50M$550.00M$481.00M$408.00M$322.90M$540.10M$357.70M$1.18B$357.90M$264.60M$147.60M
Operating Income$1.40B$1.49B$1.38B$1.18B$979.70M$555.90M$593.60M-$187.60M$805.40M$814.90M$1.06B
Depreciation & Amortization$91.50M$85.60M$72.50M$53.20M$51.30M$49.90M$49.90M$45.90M$35.90M$31.00M$31.60M
EBITDA$1.49B$1.58B$1.45B$1.24B$1.03B$605.80M$643.50M-$141.70M$841.30M$845.90M$1.09B
Net Income$1.31B$1.33B$1.20B$984.80M$727.30M$475.80Mn/an/an/an/an/a
EPS (Diluted)n/a$27.86$24.64$19.81$15.00$10.06$11.54-$2.39$13.39$9.31$15.25
Total Assets$7.22B$7.88B$7.36B$7.17B$6.04B$5.17B$4.62B$3.91B$3.40B$2.88B$2.33B
Total Liabilities$819.80M$783.80M$920.00M$1.18B$1.25B$1.21B$1.22B$1.13B$593.20M$758.40M$463.40M
Shareholders' Equity$6.40B$7.10B$6.44B$5.98B$4.80B$3.96B$3.40B$2.78B$2.79B$2.10B$1.85B
Cash & Equivalents$1.80B$1.56B$1.70B$1.21B$961.20M$894.80M$738.70M$738.40M$669.20M$705.10M$1.02B
Operating Cash Flow$1.69B$1.56B$1.33B$978.00M$802.50M$598.20M$755.70M-$206.60M$778.40M$474.20M$643.60M
Capital Expenditures$592.20M$520.50M$246.50M$230.40M$138.80M$120.80M$59.30M$83.70M$184.40M$86.30M$38.00M
Free Cash Flow$1.09B$1.04B$1.08B$747.60M$663.70M$477.40M$696.40M-$290.30M$594.00M$387.90M$605.60M
Share Repurchases$2.50B$1.00B$1.00B$0$0n/an/an/an/a$250.00M$500.00M
Shares Outstanding42.68M43.64M44.83M47.04M46.03M45.11M44.51M43.88M43.59M43.24M42.97M
Weighted Average Diluted Sharesn/a47.90M48.50M49.70M48.50M47.30M44.60M43.80M44.00M44.90M46.80M
EPS (Basic)n/a$30.13$26.44$21.04$15.98$10.60$11.65-$2.39$13.54$9.50$16.29

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView